Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and cisplatin with or without paclitaxel in recurrent/metastatic head and neck cancer
2011-002564-24Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Mar 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in head and neck squamous cell carcinoma (HNSCC) comparing Cetuximab + cisplatin with Cetuximab + cisplatin + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Mar 2012; status: completed.
02
Drugs
cetuximabcisplatinpaclitaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2011-002564-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002564-24.